Vital Signs - The Analyst's Perspective - March 2015 Issue

Vital Signs - The Analyst's Perspective - March 2015 Issue

RELEASE DATE
07-Apr-2015
REGION
North America
Research Code: 9A35-00-32-00-00
SKU: HC02612-NA-MR_16734
$500.00
In stock
SKU
HC02612-NA-MR_16734
$500.00
DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This issue of Vital Signs, released on April 3, 2015, discusses next-generation sequencing bioinformatics partnerships, FDA approval of Novartis's ZARXIO, 23andMe's foray into drug development, and Johnson & Johnson's sale of Cordis to Cardinal Health.

Table of Contents

This week's issue

Related Research
This market insight provides an analysis of the regulatory trends occurring in the US pharma/biotech industry for 2014. Included in this deliverable is an analysis of the new molecular entities (NME) approved by the US Food and Drug Administration in 2014 and predictions for 2015. Trends are showing that the US Food and Drug Administration is moving towards greater efficiency and expedited review periods, which will lead to faster access to care.
More Information
No Index No
Podcast No
Author Christi Bird
Industries Healthcare
WIP Number 9A35-00-32-00-00
Is Prebook No